These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22222285)

  • 21. The use of multi-target drugs in the treatment of neurodegenerative diseases.
    Van der Schyf CJ
    Expert Rev Clin Pharmacol; 2011 May; 4(3):293-8. PubMed ID: 22114774
    [No Abstract]   [Full Text] [Related]  

  • 22. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newsmaker interview. Genentech scientist to take the helm at Rockefeller University. Interview by Greg Miller.
    Tessier-Lavigne M
    Science; 2010 Sep; 329(5998):1456. PubMed ID: 20847242
    [No Abstract]   [Full Text] [Related]  

  • 24. Dopamine-sensitive adenylyl cyclases in neuronal development: physiopathological and pharmacological implications.
    Pavan B; Paganetto G; Dalpiaz A
    Drug Discov Today; 2011 Jun; 16(11-12):520-9. PubMed ID: 21477663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical modulators working at pharmacological interface of target proteins.
    Jeon YH; Lee JY; Kim S
    Bioorg Med Chem; 2012 Mar; 20(6):1893-901. PubMed ID: 22227462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorinated molecules in the diagnosis and treatment of neurodegenerative diseases.
    Gaye B; Adejare A
    Future Med Chem; 2009 Aug; 1(5):821-33. PubMed ID: 21426082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Emancipated' biotechs offer new drugs for neurodegeneration.
    Basu P
    Nat Med; 2003 Aug; 9(8):981. PubMed ID: 12894143
    [No Abstract]   [Full Text] [Related]  

  • 31. The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present).
    Kleczkowska P; Kowalczyk A; Lesniak A; Bujalska-Zadrozny M
    Curr Top Med Chem; 2017; 17(8):875-894. PubMed ID: 27538458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized medicine: changing the paradigm of drug development.
    Couch RD; Mott BT
    Methods Mol Biol; 2012; 823():367-78. PubMed ID: 22081358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders.
    Griffioen G
    IDrugs; 2007 Apr; 10(4):259-63. PubMed ID: 17390249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
    Kalin JH; Butler KV; Kozikowski AP
    Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
    Waldmeier PC; Tatton WG
    Drug Discov Today; 2004 Mar; 9(5):210-8. PubMed ID: 14980539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurodegenerative diseases].
    Takanashi M; Hattori N
    Nihon Rinsho; 2012 Jan; 70(1):94-8. PubMed ID: 22413500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and application of Hsp90 inhibitors.
    Solit DB; Chiosis G
    Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Metabotropic glutamate receptors as targets for new drug development].
    Arkhipov VI; Kapralova MV
    Eksp Klin Farmakol; 2011; 74(10):46-52. PubMed ID: 22238988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural Products in Drug Discovery and Development. 27-28 June 2005, London, UK.
    Harvey A
    IDrugs; 2005 Sep; 8(9):719-21. PubMed ID: 16118691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tailor-made solutions and multidirectional approach in the combat of degenerative pathologies.
    Karewicz A
    Curr Pharm Des; 2012; 18(18):2517. PubMed ID: 22512439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.